Lien, Vegard Torp; Hauge, Emily; Nuruddin, Syed; Klaveness, Jo; Olberg, Dag Erlend published the article 《Synthesis and preclinical evaluation of [18F]PF04217903, a selective MET PET tracer》. Keywords: fluorine 18 PF04217903 preparation MET kinase PET cancer imaging.They researched the compound: 2-(2-Bromoethoxy)tetrahydro-2H-pyran( cas:17739-45-6 ).Product Details of 17739-45-6. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:17739-45-6) here.
The tyrosine kinase MET (hepatocyte growth factor receptor) is abnormally activated in a wide range of cancers and is often correlated with a poor prognosis. Precision medicine with positron emission tomog. (PET) can potentially aid in the assessment of tumor biochem. and heterogeneity, which can prompt the selection of the most effective therapeutic regimes. The selective MET inhibitor PF04217903 (1) formed the basis for a bioisosteric replacement to the deoxyfluorinated analog [18F]2, intended as a PET tracer for MET. [18F]2 could be synthesized with a “”hydrous fluoroethylation”” protocol in 6.3 ± 2.6% radiochem. yield and a molar activity of >50 GBq/μmol. In vitro autoradiog. indicated that [18F]2 specifically binds to MET in PC3 tumor tissue, and in vivo biodistribution in mice showed predominantly a hepatobiliary excretion along with a low retention of radiotracer in other organs.
This literature about this compound(17739-45-6)Product Details of 17739-45-6has given us a lot of inspiration, and I hope that the research on this compound(2-(2-Bromoethoxy)tetrahydro-2H-pyran) can be further advanced. Maybe we can get more compounds in a similar way.
Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem